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Modulatory effects of rutin on the expression of cytochrome 
P450s and antioxidant enzymes in human hepatoma cells
Expression of a drug and xenobiotic metabolizing enzymes, 
cytochrome P450s (CYPs), and antioxidant enzymes can be 
modulated by various factors. The flavonoid rutin was in-
vestigated for its anti-carcinogen and protective effects as 
well as modulatory action on CYPs and phase II enzymes in 
human hepatocellular carcinoma cells. Rutin inhibited pro-
liferation of HEPG2 cells in a dose-dependent manner with 
the IC50 value of 52.7 µmol L–1 and invasion of HEPG2 cells 
(21.6 %, p = 0.0018) and colony formation of those invaded 
cells (57.4 %, p < 0.0001). Rutin treatment also significantly 
increased early/late-stage apoptosis in HEPG2 cells (28.9 %, 
p < 0.001). Treatment by rutin significantly inhibited protein 
expressions of cytochrome P450-dependent CYP3A4 (75.3 %, 
p < 0.0001), elevated CYP1A1 enzymes (1.7-fold, p = 0.0084) 
and increased protein expressions of antioxidant and phase 
II reaction catalyzing enzymes, NQO1 (2.42-fold, p < 0.0001) 
and GSTP1 (2.03-fold, p < 0.0001). Besides, rutin treatment 
significantly inhibited mRNA expression of CYP3A4 (73.2 %, 
p=0.0014). Also, CYP1A1, NQO1 and GSTP1 mRNA expres-
sions were significantly increased 2.77-fold (p = 0.029), 4.85-
fold (p = 0.0051) and 9.84-fold (p < 0.0001), respectively.
Keywords: rutin, cytochrome P450s, phase II enzymes, cell 
proliferation, HEPG2
 
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, with 
700,000 deaths annually worldwide; every year 14,000 new cases have been recorded (1). 
The main reason for the occurrence of HCC is hepatitis B (the incidence is 100-fold higher 
than in the uninfected population) and hepatitis C virus infection, as well as alcohol over-
consumption, metabolic liver diseases, obesity and type II diabetes (2, 3). 70–80 % of HCC 
resulted from cirrhosis. Depending on the stage of liver cancer, surgery, chemotherapy or 
radiotherapy is used for the treatment. On the other hand, development of new strategies 
is required for curative treatment.
Nowadays, naturally occurring phenolic compounds have become popular for the 
treatment of several diseases, including diabetes, cardiovascular diseases and cancer. Up 
SERDAR KARAKURT*
Department of Biochemistry  
Faculty of Science 














Accepted July 27, 2016 
Published online August 2, 2016
* Correspondence; e-mail: kserdar1@yahoo.com
492
S. Karakurt: Modulatory effects of rutin on the expression of cytochrome P450s and antioxidant enzymes in human hepatoma cells, 
Acta Pharm. 66 (2016) 491–502.
 
to now, 4,000 chemically different flavonoids have been reported and categorized as flavo-
nols, flavones, flavanones, catechins, anthocyanidins and chalcones (4). During daily in-
take, approximately 3–80 mg of flavonoids is consumed and average intake of flavonoids 
decreases mortality in several diseases including coronary heart disease and cancer (5). 
One of the naturally occurring flavonoids of plant origin is rutin, quercetin-3-rhamnosyl-
glucoside. This bioflavonoid cannot be synthesized by humans or animals; hence, it can be 
solely obtained from plant products (6). Administration of rutin to rat and rabbit causes 
the formation of 3,4-dihydroxyphenylacetic acid, 3-methoxy-4-hydroxyphenylacetic acid 
and m-hydroxyphenylacetic acid in urine, and quercetin-3’-O-methyl ether in bile (7). The 
microflora in lower gut hydrolyzes rutin to quercetin and isoquercetin, which are absorbed 
by the small intestine wall (8). Binding properties of rutin to metal ions, especially chelat-
ing Fe2+ and Fe3+, makes it one of the most important antioxidants since these metal ions 
are crucial for initiation of oxygen free-radical formation (9). Moreover, rutin was demon-
strated to prevent cardiovascular and neurodegenerative diseases by inhibiting lipid per-
oxidation (10). A hundred µmol L–1 of rutin also induced apoptosis in human glioblastoma 
cells by affecting the cell cycle (11). Rutin possesses anti-inflammatory (inhibiting the mu-
cosal content of platelet-activating factor, PAF) and vasoactive activity (diminishing capil-
lary permeability) as well as antioxidant activity (scavenging of hydroxyl and superoxide 
radicals) (12). Also, anti-carcinogen activity of rutin against prostate, breast, lung and co-
lon cancers was demonstrated (13, 14).
Metabolism of flavonoids and other xenobiotics (drugs, environmental pollutants and 
dietary products) was mainly accomplished by cytochrome P450 enzymes (P450s) (15). 
Among P450s, CYP3A4 is recognized as the main enzyme involved in the metabolism of 
drugs in the liver. Therefore, one of the first steps during drug development is to clarify 
interaction between the promising new drug and CYP3A4 (16). Being the large and flexible 
substrate, binding pockets allow CYP3A4 to accommodate flavonoids at multiple sites (17). 
Metabolism of P450s sometimes results in formation of superoxide radicals, which may 
cause toxicity or carcinogenesis. Hence, defense mechanism enzymes, called phase II en-
zymes, and antioxidants have been created to eliminate hazardous effects of P450s. Phase 
II enzymes, including glutathione S-transferases (GSTs) and NADPH quinone oxidoreduc-
tase I (NQO1) enzymes, cause conjugation reactions, which convert lipid soluble com-
pounds to water soluble counterparts.
The present work investigates the in vitro effects of rutin on proliferation, migration, 
invasion and colony formation properties of the human liver cancer cell line HEPG2 and 
modulation of gene and protein expression of cytochrome P450 and antioxidant enzymes.
EXPERIMENTAL
Chemicals
Rutin and bicinchoninic acid (BCA) kit for protein determination was acquired from 
Sigma-Aldrich (USA). Alamar blue was purchased from Invitrogen Life Technologies 
(USA). The CYP3A4, CYP1A1, NQO1 antibodies were obtained from Santa Cruz (USA). 
GSTP1 and GAPDH were acquired from Abcam (UK). Primers were synthesized by Iontek 
(Turkey). Eagle’s minimum essential medium (EMEM) was purchased from ATCC (Amer-
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ican Type Culture Collection, USA). All chemicals and solvents were of analytical grade 
and were obtained from commercial sources with the highest grade of purity available.
Characterization of rutin
The presence of functional groups and confirmation of rutin purity were done using 
1H NMR (Varian 400, USA) and FT-IR spectroscopy (PerkinElmer Spectrum 100, USA) in 
the spectral range of 4000–650 cm–1 with a resolution of 4 cm−1, using the ATR technique.
Cell culture and treatment
The human hepatocarcinoma cancer cell line, HEPG2, was provided from ATCC. Cell 
line was routinely cultured in EMEM supplemented with 10 % fetal bovine serum (FBS), 
100 U mL−1 penicillin, 100 µg mL−1 streptomycin and incubated at 37 °C in a humidified 
atmosphere containing 5 % CO2 in air. The cells grown were harvested by trypsinization 
and serially subcultured. The growth medium was also used for dilution of rutin.
Cell proliferation assay
HEPG2 cells were seeded at a density ranging from 1 × 103 to 1 × 105 cells mL−1 into 
96-well plate and incubated for 24 h at 37 °C in 5 % CO2 atmosphere in order to determine 
optimum cell number. The cells were treated with various concentrations of rutin, ranging 
from 1 to 200 µmol L−1, to calculate the IC50 value (half maximal inhibitory concentration). 
Cell viability was monitored by Alamar blue method, in which conversion of resazurin to 
resorufin was measured spectrophotometrically (Multiskan™ GO Microplate Spectropho-
tometer, Thermo Fisher, USA).
Colony formation assay
In order to evaluate the ability of rutin-treated HEPG2 cells for colony formation, the 
cells were plated in soft agar. Bottom agar contained 1 % agar dissolved in 2X growth me-
dium (20 % FBS, 4 mmol L–1 L-glutamine), and the top layer contained 0.7 % agar dissolved 
in normal growth medium (10 % FBS, 2 mmol L–1 L-glutamine). Top agar was then mixed 
with 5×103 cells and transferred over the agar base. Agar layers were then covered with 
EMEM and incubated at 37 °C and 5 % CO2 for 15 days. After incubation, colony fixation 
was performed using 3.7 % formaldehyde and the cells were stained with 0.1 % toluidine 
blue. Excess amount of the dye was cleaned with 10 mmol L–1 PBS.
Wound healing assay
Wound healing assay was performed using the CytoSelect™ wound healing assay kit 
(Cell Biolabs, USA). After two days of incubation of the cells with IC50-equivalent concen-
tration of rutin, the cells were detached with trypsin and 1×106 of them seeded into a 12-
well plate, in which a precise 0.9 mm gap was formed using an insert. After incubation 
with serum-free medium for 18 h, the insert was gently removed and migration of the cells 
into the wound field was monitored.
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Cell migration/invasion assay
Invasive potential of HEPG2 cells was evaluated by BD BioCoat TM Matrigel Invasion 
Chambers (BD Biosciences, USA). After two days of incubation of the cells with IC50- equiv-
alent concentration of rutin, 1×105 of the cells were harvested, re-suspended in 1 % FBS and 
placed in the upper chamber of the transwell. The cells in the upper chamber started to 
migrate to the lower chamber containing growth medium with 20 % FBS by incubation for 
24 h at 37 °C in a 5 % CO2 atmosphere. After incubation, non-invaded cells were removed 
from the upper side of the membrane with cotton swabs. Formaldehyde (3.7 %) and meth-
anol were used for fixation and permeabilization, respectively. The cells were stained with 
1 % toluidine for 15 min at room temperature for visualization. Invaded cells were photo-
graphed under the inverted microscope and counted.
Apoptosis assays
Flow cytometric analysis was performed to assess the apoptosis and necrosis rates of 
HEPG2 cells before and after the treatment with rutin. Following the treatment with IC50- 
equivalent concentration of rutin, the cells were incubated for 48 hours and detached with 
trypsin. Then, the cells were stained with Annexin V-APC and 7-AAD antibodies (BD 
Biosciences) at room temperature to detect the apoptosis and necrosis rates. The analyses 
were performed using flow cytometry (Beckman Coulter Navios, USA).
cDNA synthesis and quantitative mRNA expression by real-time PCR
Quantitative real-time RT-PCR was used to investigate the differences in the expres-
sion of mRNA of cytochrome P450 enzymes and phase II enzymes. HepG2 cells were 
transfected with a concentration equivalent to rutin IC50 value for 2 days. Cells were then 
washed with PBS and lysed with QIAzol reagent (Qiagen, USA) for dissociation of any 
RNA-protein complexes. Chloroform was added for phase separation, followed by aque-
ous precipitation of total RNA using isopropyl alcohol. One microgram of total RNA was 
reversely transcribed into cDNA using a QuantiTect reverse transcription kit (Qiagen). 
Quantitative and qualitative analyses of RNA and cDNA were measured at NanoDrop™ 
2000 (Thermo Scientific, USA). qRT-PCR was performed with primers for NQO1, GSTP1, 
GSTM1, CYP1A1, CYP3A4 and CYP17A1 with a QuantiTect SYBR Green PCR kit in the 
BioRad CFX96 real time PCR detection system (Bio-Rad, USA). Housekeeping gene, GAP-
DH, which is assumed to be expressed at a constant level, was used as normalizer. Fold 
change was calculated from: 2-∆∆Ct
where ∆∆Ct = ∆Ct(treated) – ∆Ct(control), ∆Ct(treated) = ∆Ct(CYPs) – ∆Ct(GAPDH), 
∆Ct(control) = ∆Ct (CYPs) – ∆Ct(GAPDH).
The primers used for qRT-PCR measurement were: GAPDH forward 5′-GGA GCG 
AGA TCC CTC CAA AAT-3′ and reverse 5′-GGC TGT TGT CAT ACT TCT CAT GG-
3’, NQO1 forward 5′-GAA GAG CAC TGA TCG TAC TGG C-3′ and reverse 5′-GGA TAC 
TGA AAG TTC GCA GGG-3′, GSTP1 forward 5′-CCC TAC ACC GTG GTC TAT TTC C-3′ 
and reverse 5′-CAG GAG GCT TTG AGT GAG C-3′, GSTM1 forward 5′-TCT GCC CTA CTT 
GAT TGA TGG G-3′ and reverse 5′-TCC ACA CGA ATC TTC TCC TCT-3′, CYP1A1 forward 
5′-TAC CTC AGC AGC CAC CTC CAA G-3’ and reverse 5′-GGC CCT GAT TAC CCA GAA 
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TAC C-3′, CYP3A4 forward 5′-AAG TCG CCT CGA AGA TAC ACA-3′ and reverse 5′-AAG 
GAG AGA ACA CTG CTC GTG-3′, CYP17A1 forward 5′-GCT GCT TAC CCT AGC TTA TTT 
GT-3′ and reverse 5′-ACC GAA TAG ATG GGG CCA TAT TT-3’.
Western blot analysis
Three days after rutin treatment, proteins in HepG2 cells were extracted with RIPA 
lysis buffer (Applygen, China). Total protein concentrations of the control and rutin-treat-
ed groups were determined with a commercial BCA kit. Ten μg from the samples were 
loaded into each well and further separated on 7.5 % (for CYP1A1 and CYP3A4) and 10 % 
(for GSTP1, NQO1 and GAPDH) separating gels in SDS-page electrophoresis. Protein 
bands were transferred to 0.45-μm nitrocellulose membranes (Bio-Rad) and blocked with 
5 % non-fat dry milk for 1 h at room temperature. The membranes were further incubated 
with specific primary antibodies against CYP1A1, CYP3A4, GSTP1 and NQO1, then with 
secondary HRP-labeled antibodies, and finally visualized using enhanced chemilumines-
cence (ECL) solution. Density of protein bands was measured using the Image J software.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (GraphPad Software v5.0, 
USA). A two-tailed Student’s t-test was used to compare the two groups. Results were 
expressed as mean ± standard deviation (SD) of three independent experiments and a p-
value < 0.05 indicated statistical significance.
RESULTS AND DISCUSSION
The presence of phenolic OH and aromatic H in rutin were proven via 1H NMR spec-
tra (Fig. 1). At δ 12.58, 10.81, 9.65 and 9.18 ppm, signals showed the existence of phenolic OH 
and the signals at δ 7.51, 6.82, 6.36 and 6.18 ppm showed the presence of aromatic protons. 
Methyl (CH3) and methylene (CH2) protons were also observed as doublets at δ 5.17 and 
5.08 ppm. In the FT-IR spectra, rutin functional groups were also observed. The peaks at 
3414 and 3334 cm-1 proved the presence of alcohol O-H and phenolic O-H, respectively. 
Moreover, the peaks at 1661 and 1593 cm–1 belonged to carbonyl (C=O) and aromatic C=C 
bands, respectively.
Migration, invasion and colony formation ability of human hepatocellular carcinoma 
cell line HEPG2 and the possible effects of rutin on that cell were investigated under in 
vitro conditions.
Cytotoxic effect of rutin on HEPG2 cells was determined using the Alamar blue assay. 
As shown in Fig. 2a, rutin was demonstrated to have a dose-dependent inhibitory action 
on the viability of HEPG2 cells and IC50 value was calculated as 52.7 μmol L–1, by using 
sigmoidal plot of log rutin concentration vs. cell viability (Fig. 2b). To clarify optimum 
growth time and cell number, different numbers of HEPG2 cells were incubated in 6-, 12-, 
24- and 96-well plates at 37 °C in 5 % CO2. Effect of rutin on the growth of HEPG2 cells was 
also determined and optimum incubation time for further studies was determined. Trans-
fection day was accepted as day 1 and rutin significantly showed its action on cell growth 
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on day 3. Since the untreated cells became confluent between days 4 and 5, the experiment 
was stopped at day 5 (Fig. 2c). In order to understand the reason for cell death, the effect of 
rutin on apoptosis-induced cell death was also investigated using flow cytometry after 
Annexin V-APC and 7-AAD staining. Treatment by 52.7 μmol L–1 of rutin significantly 
increased (28.9 %) early- and late-stage apoptosis in HEPG2 cells (Fig. 2d).
Wound healing assay was conducted to observe the effects of rutin on the mobility of 
HEPG2 cells (Fig. 3a). Analysis of wound migration (Fig. 3b) showed that rutin, at 52.7 
µmol L–1 significantly inhibited migration of HEPG2 cells. Moreover, anti-invasive poten-
tial of rutin was also demonstrated by the Matrigel invasion assay (Fig. 3c) when rutin 
significantly (21.6 %, p = 0.0018) inhibited invasion of HEPG2 cells. Besides, treatment with 
rutin inhibited 57.4 % (p < 0.0001) of colony formation of the invaded cells (Fig. 3d).
In general, treatment of cancerous cell lines with phenolics and flavonoids in particu-
lar resulted in inhibition of bioactivating CYP enzyme expressions (18). Decreased level of 
CYPs prevented formation of toxic metabolites as well as superoxide radicals. CYP3A4 is 
the dominant P450 enzyme and is responsible for the metabolism of more than 60 % of 
clinical drugs (19); it starts to express after the postnatal period. A primary form, CYP3A7, 
is found prominently in human fetal liver microsomes (20). The treatment with rutin in-
hibited mRNA and protein expression of CYP3A4 enzyme by 73.2 and 75.3 %, respectively. 
Fig. 1. Spectral characterization of rutin: a) chemical structure of rutin; b) functional groups of rutin 
by FT-IR; c) 1H NMR spectrum of rutin.
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Inhibition of this CYP isoform resulted in the alteration of the metabolism of chemothera-
peutic drugs used in HCC (16). During combination chemotherapy, the metabolism of the 
main drug generally requires modification of its regulator by another molecule. Hence, a 
decreased level of CY3A4 after rutin treatment may increase the efficacy of CYP3A4 inac-
tivating drugs. On the other hand, in many studies, the treatment with flavonoids such as 
quercetin resulted in induction of CYP1A1 expression (21–23). This is also supported by 
this study’s results (1.7-fold and 2.77-fold induction in protein and mRNA expression, re-
spectively).
Notably, rutin treatment significantly affected protein expression of the drug metabo-
lizing CYP3A4 and CYP1A1, and phase II reaction catalyzing NQO1 and GSTP1 enzymes. 
Quantitative and comparative analyses were done using Western blotting. Analysis of 
band density (Fig. 4b) showed that treatment with rutin significantly reduced CYP3A4 
protein expression in HEPG2 (75.3 %, p < 0.0001). On the other hand, interestingly, the 
other cytochrome P450 dependent enzyme CYP1A1 protein expression (Fig. 4c) was in-
Fig. 2. Effects of rutin on viability and proliferation of HEPG2 cells: a) viability of HEPG2 cells after 
treatment with different concentrations of rutin measured by Alamar blue assay; b) IC50 value of rutin 
on HEPG2 cells determined from sigmoidal plot of rutin concentration vs. cell viability; c) Effect of 
rutin on growth of HEPG2 cells on time scale; d) Effect of rutin on apoptosis-induced cell death ex-
amined by flow cytometry following Annexin V-APC and 7-AAD staining. The data of a) and c) are 
presented as mean ± SD, n = 3. *Statistically significant difference vs. control: p < 0.05.
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creased 1.7-fold (p = 0.0084). Besides, antioxidant and phase II reaction catalyzing NQO1 
and GSTP1 protein expressions were also elevated 2.42- and 2.03-fold, respectively (Figs. 
4d,e).
GSP1 is one of the tumor suppressor genes evaluated in many cancer types. Hyper-
methylation of cysteine which is found in CpG island promoter region causes the loss of 
GSTP1 activity. Inactivation of GSP1 was found to be associated with the increased risk 
and shortened survival in patients with HCC (24, 25). This study showed that the mRNA 
expression elevation was observed in the expression of GSTP1 (9.84-fold), which may be 
due to demethylation of this promotor region. NQO1, one of the other phase II and anti-
oxidant enzymes, ubiquitously expressed not only in liver but also in other tissues such as 
lung, colon and breast (26–28). Decreased level of NQO1 activity due to genetic polymor-
phisms also increases the incidence of HCC (29, 30). On the other hand, the increased 
level of NQO1 expression was demonstrated to possess protective role in cellular defense 
Fig. 3. Effects of rutin on proliferation, migration, invasion and colony formation of HEPG2 cells: a) 
representative images of wound healing assay: a-1 (0 h)/a-3 (48 h) and a-2 (0 h)/a-4 (48 h) for control 
and rutin groups, resp; b-d): Quantitative analyses of migration, invasion and colony formation (rates 
were calculated based on the cell number). Mean ± SD of three experiments performed in duplicate. 
*Statistically significant difference vs. control: p < 0.05.
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during carcinogenesis (31). As seen in Fig. 5, treatment with 52.7 μmol L–1 rutin signifi-
cantly inhibited mRNA expression of CYP3A4 (73.2 %, p = 0.0014) while CYP1A1, NQO1 
and GSTP1 mRNA expressions were increased 2.77- (p = 0.029), 4.85- (p = 0.0051) and 9.84-
fold (p < 0.0001), respectively.
CONCLUSIONS
In conclusion, the naturally occurring flavonoid rutin significantly inhibited progres-
sion of HCC cells. The compound was found remarkably effective on migration, colony 
formation and invasive potential of HEPG2 cells. Rutin was found to be a very potent in-
hibitor of CYP3A4 and activator of GSTP1 and NQO1. On the other hand, it should be 
noted that the in vitro inhibiting and activating potential of rutin on HCC must be sup-
ported by in vivo studies.
Fig. 4. Effects of rutin on protein expression of cytochrome P450 dependent CYP3A4 and CYP1A1 and 
phase II reaction catalyzing NQO1 and GSTP1 of human hepatocellular carcinoma cell line HEPG2. 
a) Representative immunoblot of HEPG2 cells’ protein in experimental control and rutin treated 
groups. b)-e): Analysis of band density of protein expression of the control and rutin treated groups. 
The data are presented as mean ± SD, n=3. Statistically significant difference vs. control: *p<0.05, 
**p<0.001.
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